Positive Results Published from 9-Month Clinical Trial of a Generic Glatiramer Acetate in Relapsing-

  • In a nine-month study of 794 people with relapsing-remitting MS, GTR (generic glatiramer acetate, Synthon BV) reduced disease activity on MRI scans similarly to Copaxone® (glatiramer acetate, Teva Pharmaceutical Industries Ltd).
  • This study has been published in JAMA Neurology (Published Online October 12, 2015).
  • An April 28, 2015 press release notes that safety and effectiveness were maintained over two years in an extension study, results of which have not yet been published.
  • Synthon has filed Abbreviated New Drug Applications with the U.S. FDA for approval…

    Favicon of www.nationalmssociety.org da : www.nationalmssociety.org

    Prosegui la lettura...
    Traduci l'articolo...

    Sclerosi Multipla News

    Potrebbe interessarti anche

Argomenti correlati